A Study of Lasmiditan (LY573144) in Children Aged 6 to 17 With Migraine
Status:
Completed
Trial end date:
2020-02-24
Target enrollment:
Participant gender:
Summary
The purpose of the study is the measure the levels of lasmiditan in the body of children aged
6 to 17 with migraine. The study also will also examine the safety and tolerability of
lasmiditan in children aged 6 to 17 with migraine.
The study will last about 6 weeks, and includes 4 visits.